Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01)

Cancer Communications · Published 2025-11-22 · DOI 10.1002/cac2.70080

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1002/cac2.70080

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high‐throughput personalized drug discovery · Cancer Communications · 2025 · Same journal
• A practical overview and statistical analysis of interval‐censored data in cancer · Cancer Communications · 2025 · Same journal
• The Roles of Protein S -Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potential · Cancer Communications · 2026 · Same journal
• WTAP-Mediated Glutaminase Splicing Bias Suppresses Ferroptosis in Hepatocellular Carcinoma · Cancer Communications · 2026 · Same journal
• Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma · Cancer Communications · 2026 · Same journal
• CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer · Cancer Communications · 2025 · Same journal
• Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of the CinClare trial · Cancer Communications · 2025 · Same journal
• HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism · Cancer Communications · 2025 · Same journal
• Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study · Cancer Communications · 2026 · Same journal
• Multiplexed CRISPR/Cas9 Editing of Tumor Suppressor Genes in the Mouse Endometrium Recapitulates High-Risk Endometrial Carcinoma · Cancer Communications · 2026 · Same journal